ESTRO 2025 - Abstract Book

S2050

Clinical - Urology

ESTRO 2025

Conclusion: Our results demonstrate that re-irradiating the pelvis with SBRT is a safe and effective management strategy in the oligometastatic setting. This research will add to the restricted data available 1,2,3 and give clinicians confidence in re irradiating the pelvic region following radical radiotherapy treatment, offering a durable response with low-risk side effect profile.

Keywords: Prostate, Re-irradiation, SBRT

References: 1. Di Franco R, Borzillo V, Scipilliti E et al. Reirradiation of Locally Recurrent Prostate Cancer with Cyberknife® System or Volumetric Modulated Arc Therapy (VMAT) and IGRT-Clarity®: Outcomes, Toxicities and Dosimetric Evaluation. Cancers (Basel). 2022 Jun 29;14(13):3187. 2. Loi M, Di Cataldo V, Francolini G et al. Single-Fraction Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Relapse in Prostate Cancer. Oncol Res Treat. 2018;41(11):703-705. 3. Morgan TM, Boorjian SA, Buyyounouski MK et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 Apr;211(4):526-532.

3482

Digital Poster Application of Radiotherapy Combined with Immunotherapy in UTUC Xuemin Li, Ran Peng, Hao Wang Radiation Oncology, Peking University Third Hospital, Beijing, China

Purpose/Objective: This study aimed to evaluate the safety and efficacy of RT combined with immunotherapy in UTUC.

Material/Methods: A total of 19 patients with UTUC with renal dysfunction were retrospectively included. The treatment protocol consisted of RT followed by sequential maintenance immunotherapy. The median follow-up duration was 16.2 months (range: 1.7 – 47.6 months). Among the 15 patients with radiographically measurable lesions, there were 39 metastatic sites in total, of which 27 were treated with RT, and 11 patients received comprehensive RT coverage.